Table 3:

Results of regression analysis to determine associations between periods, tumor subtypes, and clinical tumor size for SLNB versus ALND, and clinical lymph node status for cT2-3-4 versus cT0-1, and clinical tumor size and clinical lymph node status for mastectomy versus breast conservative surgery.

			CI 95%
	p-value	OR	Inferior	Superior
SLNB versus ALND
Luminal A		1
Luminal B Her2−	0.206	1.462	0.811	2.634
Luminal B Her2+	0.053	1.631	0.994	2.677
Her2+	0.355	1.286	0.754	2.193
Triple Negative	<0.0001	2.332	1.511	3.597
cT0-1		1
cT2	0.086	1.431	0.95	2.154
cT3	<0.0001	0.254	0.147	0.44
cT4	0.003	0.041	0.005	0.329
P1		1
P2	<0.0001	3.567	2.12	6.001
P3	0.008	1.877	1.181	2.983
cT2-3-4 versus cT0-1
P1		1
P2	0.371	0.771	0.435	1.365
P3	<0.0001	0.27	0.162	0.45
Luminal A		1
Lum B Her2−	0.981	1.006	0.606	1.671
Lum B Her2+	0.385	1.211	0.786	1.868
Her2+	0.062	1.617	0.976	2.681
Triple Neg	0.163	1.315	0.895	1.933
cN0		1
cN>=1	<0.0001	1.748	1.306	2.34
mastectomy versus BCS
P1		1
P2	0.224	0.818	0.591	1.131
P3	0.114	0.778	0.57	1.062
cT0-1		1
cT2	0.381	0.877	0.653	1.177
cT3	<0.0001	2.974	2.058	4.298
cT4	<0.0001	6.469	3.324	12.589
Luminal A		1
Lum B Her2−	0.085	0.725	0.503	1.045
Lum B Her2+	0.662	0.93	0.673	1.287
Her2+	0.259	1.234	0.856	1.779
Triple Neg	<0.0001	0.567	0.426	0.756
cN0		1
cN1	<0.0001	1.518	1.223	1.883
cNx	0.684	1.223	0.464	3.222

Abbreviations: cT, clinical tumor size stage; cN, clinical lymph node status; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; BCS, breast conservative surgery.